Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Plain-language summary

This study examines Sorafenib as a salvage treatment in patients with relapsed or refractory acute myeloid leukemia carrying FLT3-ITD. Eligible patients have an FLT3 mutation and persistent leukemia despite at least two prior chemotherapy regimens. It was conducted in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

The University of Hong Kong

Intervention

Sorafenib 200mg

Start date

11/15/2010

Estimated completion

3/1/2020

Countries

Hong Kong

Related genes

Locations

• Hong Kong, Hong Kong

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* 1\. Patients with AML carrying Flt3 mutation; AND,
* 2\. Patients with persistent leukemia despite at least two prior chemotherapy regimens

Exclusion Criteria:

* Patients who are considered not fit for any form of leukemia treatment by the attending hematologists